Academic Journal
Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis
| العنوان: | Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis |
|---|---|
| المؤلفون: | Matthias Augustin, Andrea Bauer, Konstantin Ertner, Ralph von Kiedrowski, Florian Schenck, Jutta Ramaker-Brunke, Sophie Möller, Anja Fait, Mike Bastian, Diamant Thaçi |
| المصدر: | Dermatology and Therapy, Vol 13, Iss 3, Pp 803-816 (2023) |
| بيانات النشر: | Adis, Springer Healthcare, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Dermatology |
| مصطلحات موضوعية: | Atopic dermatitis, Biologic, Dupilumab, Real-world evidence, Dermatology, RL1-803 |
| الوصف: | Abstract Introduction Dupilumab has significantly improved the signs, symptoms and quality of life (QoL) of patients with moderate-to-severe atopic dermatitis (AD) in randomised, controlled clinical trials. However, there is a need to assess the effectiveness and safety of dupilumab in real-world clinical practice. The PROLEAD study was designed to examine the effectiveness and safety of dupilumab in moderate-to-severe AD in a real-world setting in Germany. Here, we present 12-week effectiveness and safety results with dupilumab from PROLEAD. Methods PROLEAD is a multicentre, prospective, non-interventional study being conducted at 126 routine care sites across Germany. Adults with moderate-to-severe AD who require systemic therapy were treated with dupilumab as indicated by the Summary of Product Characteristics. Data collected included physician assessments (EASI, BSA, SCORAD, and IGA) and patient-reported outcomes (PROs [POEM, DLQI, EQ-5D-5L, Peak Pruritus NRS and MOS Sleep Scale]). Results Of 839 patients assessed for eligibility, 828 were included. The full analysis and safety analysis sets comprised 775 and 818 patients, respectively. The number of patients receiving concomitant therapy decreased from baseline to Week 12. Mean (standard deviation [SD]) percentage change in EASI score from baseline to Week 12 was –67.5% (48.4%) and was comparable across the four body regions. The proportion of patients achieving EASI-75 was 59.4% at Week 12. Mean (SD) Peak Pruritus NRS decreased from 7.4 (2.3) at baseline to 3.4 (2.6) at Week 12. Improvements from baseline to Week 12 were reported in all PROs assessed. No new safety signals were observed. Discussion Improvements in efficacy outcomes and adverse event rates in a real-world setting were more favourable than in phase 3 clinical trials. Conclusions The 12-week findings of PROLEAD demonstrate that treatment with dupilumab is effective and well tolerated, with rapid onset of action in signs, symptoms and QoL in patients with moderate-to-severe AD in the real world. Trial Registration Number DUPILL08907; NIS-Nr. 433. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8210 2190-9172 |
| Relation: | https://doaj.org/toc/2193-8210; https://doaj.org/toc/2190-9172 |
| DOI: | 10.1007/s13555-023-00894-3 |
| URL الوصول: | https://doaj.org/article/6709c8efa6eb48a8b6a6220b730780b3 |
| رقم الانضمام: | edsdoj.6709c8efa6eb48a8b6a6220b730780b3 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 21938210 21909172 |
|---|---|
| DOI: | 10.1007/s13555-023-00894-3 |